Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.79 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.79 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.79 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 10/20 | 0.52 |
| ▸ | TCF7L2 | Q9NQB0 | 10/20 | 0.52 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641690 | 0.79 | CTNNB1 (0.76) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL3643545 | 0.79 | CTNNB1 (0.66) | HRH4CTNNB1TCF7L2 | |
| SCHEMBL3639927 | 0.78 | CTNNB1 (0.76) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL3774097 | 0.77 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL29143528 | 0.76 | CTNNB1 (0.59) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL20399843 | 0.76 | CTNNB1 (0.56) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL20399100 | 0.76 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL26746341 | 0.76 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL14504164 | 0.76 | HTT (0.54) | CTNNB1TCF7L2ALDH1A1NPSR1 | |
| SCHEMBL3644600 | 0.76 | CTNNB1 (0.55) | PDE4APDE4BPDE4CPDE4DHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | claimed |
| WO-2018134685-A2 | COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2018-07-26 | — | — | WO | claimed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
| WO-2018134685-A2 | COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | PWWP2B, WARS1, PNPO | PDE4A 2407/4885PDE4B 2583/4885PDE4C 1948/4885 |
| US-20190345157-A1 | COMPOUNDS | ABCB11, LTC4S, AQP1 | PDE4A 1803/4885PDE4B 1397/4885PDE4C 1358/4885 |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | P2RX5, PNPO, P2RX3 | PDE4A 2160/4885PDE4B 1985/4885PDE4C 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.